---
audienceLevel: patient
cancerTypes:
- bladder
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Zanidatamab-hrii - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/zanidatamab-hrii
version: v1
---

# Zanidatamab-hrii - NCI

# Zanidatamab-hrii

Placeholder slot

(ZAN-ih-DA-tuh-mab)

Zanidatamab-hrii
works by binding to two specific sites on the HER2 protein, which is found in high levels on the surface of some cancer cells. This binding damages the HER2 protein and lowers the amount of it on the cell surface. Zanidatamab-hrii also helps the immune system kill cancer cells. These combined actions may slow or stop the growth of HER2-positive cancer cells. Zanidatamab-hrii is a type of targeted therapy called a bispecific HER2-directed antibody.

US Brand Name(s)

Ziihera

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae5d9425-fae5-4541-a158-150998343348&audience=consumer)

## Use in Cancer

Zanidatamab-hrii
is approved to treat adults with:

- **[biliary tract cancer](/Common/PopUps/popDefinition.aspx?id=811566&version=Patient&language=English)**, including [cholangiocarcinoma](/Common/PopUps/popDefinition.aspx?id=335064&version=Patient&language=English) and [gallbladder cancer](/Common/PopUps/popDefinition.aspx?id=446566&version=Patient&language=English), that cannot be removed by surgery or has spread to other parts of the body, has been treated with other therapies, and is [HER2 positive](/Common/PopUps/popDefinition.aspx?id=737998&version=Patient&language=English)

Zanidatamab-hrii is approved under FDAâ€™s Accelerated Approval Program. As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that it provides a clinical benefit in these patients.

Zanidatamab-hrii
is also being studied in the treatment of other types of
cancer.

## More About Zanidatamab-hrii

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/784826) - Detailed scientific definition and other names for this drug.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Zanidatamab-hrii](https://www.cancer.gov/research/participate/clinical-trials/intervention/C130010) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
